Overview

Delivery of Malaria Chemoprevention in the Post-discharge Management of Children With Severe Anaemia in Malawi

Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Background and rationale: Children hospitalised with severe anaemia in Africa are at high risk of readmission or death within 6 months after discharge. No strategy specifically addresses this post-discharge period. In Malawi, 3 months of post-discharge malaria chemoprevention (PMC) with monthly 3-day treatment courses of artemether-lumefantrine (AL) in children with severe malarial anaemia prevented 31% of deaths and readmissions. The effect was in addition to the effect of insecticide-treated bednets. There is now need to design and evaluate effective delivery mechanism for PMC within the health system.
Phase:
Phase 3
Details
Lead Sponsor:
University of Malawi College of Medicine
Collaborators:
Imperial College London
Kenya Medical Research Institute
Liverpool School of Tropical Medicine
London School of Hygiene and Tropical Medicine
Makerere University
Ministry of Health and Population, Malawi
Ministry of Health, Malawi
The Research Council of Norway
Universiteit van Amsterdam
University of Amsterdam
University of Bergen
University of Minnesota
University of Minnesota, MN
Treatments:
Artemisinins
Artenimol
Dihydroartemisinin
Piperaquine